Strategic Growth Aenova’s position as a leading global CDMO with a turnover of about 750 million euros and ongoing investments in development and manufacturing capacity signals ongoing demand for contract development, manufacturing, and specialized technologies. This presents opportunities to offer expanded CDMO services, scale-up capabilities, and advanced manufacturing partnerships across human and animal health products.

Technology Forward The tech stack indicates mature digital and cloud-enabled operations, including Terraform, Drupal, Azure Active Directory, Smartsheet, and collaboration tools. Sales teams can position value around scalable GMP-compliant digital workflows, secure data management, and efficient program management for clients seeking modernized CDMO partnerships.

Innovation Focus Recent milestones such as the spray drying platform launch and expansion for amorphous solid dispersions and inhalation powders highlight a capability draw for customers with complex formulations or novel delivery systems. This creates cross-sell opportunities in formulation development, process optimization, and specialty manufacturing.

Leadership Momentum New appointments of a Managing Director for the Latina site and a Chief Operating Officer reflect strategic leadership and potential regional expansion. There is an opening for targeted engagements with European and LATAM clients seeking reliable multi-site CDMO support and cross-border supply chain resilience.

Sustainability Advantage Recognition for sustainability at major industry events and ongoing investments reinforce Aenova as a sustainability-conscious partner. Positioning opportunities exist to collaborate on environmentally responsible manufacturing, green packaging, and life-cycle sustainability programs for customers with ESG goals.